Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1114

1.

A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.

Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, Turchin PI, Mark L, Garrison AE, Valenzano KJ.

Eur J Pharmacol. 2005 Dec 28;528(1-3):65-72. Epub 2005 Nov 28.

PMID:
16316650
2.

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.

Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT.

Neuropharmacology. 2005 Apr;48(5):658-72.

PMID:
15814101
3.

Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.

Sain NM, Liang A, Kane SA, Urban MO.

Neuropharmacology. 2009 Sep;57(3):235-41. doi: 10.1016/j.neuropharm.2009.06.004. Epub 2009 Jun 16.

PMID:
19538975
4.

Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833.

Hu B, Doods H, Treede RD, Ceci A.

Pain. 2009 Jun;143(3):206-12. doi: 10.1016/j.pain.2009.02.018. Epub 2009 Apr 3.

PMID:
19345493
5.

3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.

De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H, Mauler F.

J Pharmacol Exp Ther. 2004 Aug;310(2):620-32. Epub 2004 May 12.

PMID:
15140913
6.

Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.

Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD.

J Pharmacol Exp Ther. 2009 Jan;328(1):141-51. doi: 10.1124/jpet.108.145011. Epub 2008 Oct 17.

PMID:
18931146
7.

Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.

LaBuda CJ, Koblish M, Little PJ.

Eur J Pharmacol. 2005 Dec 19;527(1-3):172-4. Epub 2005 Nov 28.

PMID:
16316653
8.

Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice.

Li AL, Carey LM, Mackie K, Hohmann AG.

J Pharmacol Exp Ther. 2017 Aug;362(2):296-305. doi: 10.1124/jpet.117.241901. Epub 2017 Jun 7.

9.

CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.

Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, Kato T, Okumura Y, Takada J.

J Pharmacol Exp Ther. 2007 Aug;322(2):686-94. Epub 2007 May 10.

PMID:
17495127
10.

Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.

Nirogi R, Jabaris SL, Jayarajan P, Abraham R, Shanmuganathan D, Rasheed MA, Royapalley PK, Goura V.

Eur J Pharmacol. 2011 Oct 1;668(1-2):155-62. doi: 10.1016/j.ejphar.2011.06.032. Epub 2011 Jul 3. Erratum in: Eur J Pharmacol. 2011 Dec 30;673(1-3):101. Jabaris, Sugin Lal [added].

PMID:
21756895
11.

Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.

Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D.

Eur J Neurosci. 2003 Jun;17(12):2750-4.

PMID:
12823482
12.

Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.

Schiene K, De Vry J, Tzschentke TM.

J Pharmacol Exp Ther. 2011 Nov;339(2):537-44. doi: 10.1124/jpet.111.181263. Epub 2011 Aug 4.

PMID:
21816956
13.

In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models.

Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, Grayson GK, Zhu CZ, Pai M, Chandran P, Salyers AK, Wensink EJ, Honore P, Sullivan JP, Dart MJ, Meyer MD.

Br J Pharmacol. 2008 Jan;153(2):390-401. Epub 2007 Nov 12.

14.

CB2 cannabinoid receptor mediation of antinociception.

Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP Jr.

Pain. 2006 May;122(1-2):36-42. Epub 2006 Mar 23.

PMID:
16563625
16.

Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist.

Porreca F, Vanderah TW, Guo W, Barth M, Dodey P, Peyrou V, Luccarini JM, Junien JL, Pruneau D.

J Pharmacol Exp Ther. 2006 Jul;318(1):195-205. Epub 2006 Mar 24.

PMID:
16565167
17.

Studies with ketamine and alfentanil following Freund's complete adjuvant-induced inflammation in rats.

Edwards SR, Mather LE, Smith MT.

Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):414-20.

PMID:
17439409
18.

Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.

Leánez S, Hervera A, Pol O.

Eur J Pharmacol. 2009 Jan 5;602(1):41-9. doi: 10.1016/j.ejphar.2008.11.019. Epub 2008 Nov 18.

PMID:
19041302
19.

N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.

Quintão NL, da Silva GF, Antonialli CS, de Campos-Buzzi F, Corrêa R, Filho VC.

Anesth Analg. 2010 Mar 1;110(3):942-50. doi: 10.1213/ANE.0b013e3181cbd7f6.

PMID:
20185671
20.

The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2 receptors during neuropathic pain in mice.

Hervera A, Negrete R, Leánez S, Martín-Campos J, Pol O.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):887-96. doi: 10.1124/jpet.110.167585. Epub 2010 May 24.

PMID:
20498253

Supplemental Content

Support Center